Verona Pharma Plc ADR (NASDAQ: VRNA) started the day on Wednesday, with a price increase of 1.54% at $34.19, before settling in for the price of $33.67 at the close. Taking a more long-term approach, VRNA posted a 52-week range of $11.39-$35.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been -39.77% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 19.36%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -222.22%. This publicly-traded company’s shares outstanding now amounts to $80.44 million, simultaneously with a float of $62.79 million. The organization now has a market capitalization sitting at $2.77 billion. At the time of writing, stock’s 50-day Moving Average stood at $30.33, while the 200-day Moving Average is $20.42.
Verona Pharma Plc ADR (VRNA) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Verona Pharma Plc ADR’s current insider ownership accounts for 22.56%, in contrast to 62.28% institutional ownership. According to the most recent insider trade that took place on Oct 24 ’24, this organization’s Chief Financial Officer sold 141,360 shares at the rate of 4.38, making the entire transaction reach 618,761 in total value, affecting insider ownership by 13,672,560. Preceding that transaction, on Oct 25 ’24, Company’s Chief Financial Officer sold 3,200 for 4.38, making the whole transaction’s value amount to 14,000. This particular insider is now the holder of 13,669,360 in total.
Verona Pharma Plc ADR (VRNA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
Verona Pharma Plc ADR’s EPS decrease for this current 12-month fiscal period is -222.22% and is forecasted to reach -0.21 in the upcoming year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
Let’s observe the current performance indicators for Verona Pharma Plc ADR (VRNA). It’s Quick Ratio in the last reported quarter now stands at 8.61. The Stock has managed to achieve an average true range (ATR) of 1.32.
In the same vein, VRNA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.56, a figure that is expected to reach -0.07 in the next quarter, and analysts are predicting that it will be -0.21 at the market close of one year from today.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
If we take a close look at the recent performances of Verona Pharma Plc ADR (NASDAQ: VRNA), its last 5-days Average volume was 0.76 million that shows plunge from its year to date volume of 0.91 million. During the previous 9 days, stock’s Stochastic %D was recorded 26.27% While, its Average True Range was 1.27.
Raw Stochastic average of Verona Pharma Plc ADR (VRNA) in the period of the previous 100 days is set at 93.96%, which indicates a major rise in contrast to 68.22% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 30.80% that was lower than 64.02% volatility it exhibited in the past 100-days period.
